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Arg’-vasopressin i hibited the adenylate cyclase activity of human platelet particulate fraction up to a 
maximum of 27% (I& = 1.2 nM). This inhibition required the presence of 10 pM GTP and was optimal 
with 100 mM NaCl. Orn*-vasopressin had similar effects. 1-Deamino-Val”, D-Arg*-vasopressin d dnot by 
itself affect adenylate cyclase activity but competitively inhibited the action of Arg*-vasopressin (PAZ = 
7.74). Arg’-vasopressin did not inhibit adenylate cyclase in intact platelets but instead caused platelet 
aggregation, an effect that was also competitively inhibited by I-deamino-Va14, D-Arg’-vasopressin 
(PAZ = 7.82). Thus, platelets possess vasopressin receptors of the V1 type that, under appropriate 
conditions, can mediate ither inhibition of platelet adenylate cyclase or platelet aggregation. 
Vasopressin Adenylate cyclase 
1. INTRODUCTION 
Vasopressin receptors can be classified into two 
principal types on the basis of structure-activity 
and binding studies with vasopressin analogues 
[1,2]. These receptor types mediate the classical 
pressor and antidiuretic actions of AVP. Authors 
in [3] have termed the former, Vr-receptors; these 
also appear to mediate the glycogenolytic action of 
vasopressin on hepatocytes and to act by 
stimulating phosphoinositide breakdown and Ca2+ 
mobilization. Antidiuretic receptors, which ac- 
tivate adenylate cyclase, were termed Vz-receptors. 
Relatively specific agonists and antagonists acting 
at these receptors have been synthesized and it is of 
particular interest that some potent antidiuretic 
agonists (e.g., dVDAVP) are potent pressor an- 
tagonists [11. AVP is also an inducer of platelet ag- 
gregation [4]. Initial studies with analogues sug- 
gested that this effect of AVP resembled its pressor 
Abbreviations: AVP, Arg’-vasopressin; OVP, 
Orn*-vasopressin; dVDAVP, l-deamino-Va14, D- 
Arg*-vasopressin; EGTA, ethylene glycol bis (&- 
aminoethyl ether)-N,N,N ‘,N’-tetraacetic acid 
Receptor Platelet aggregation 
action [4], a finding that has recently been con- 
firmed using a specific antagonist [5]. 
In contrast to agonists such as epinephrine, 
acetylcholine and angiotensin II [6,7], which can 
also mobilize Cu’+ ions, AVP has not been observ- 
ed to inhibit adenylate cyclase in broken cell 
preparations from any tissue so far examined [2,7]. 
Moreover, experiments with platelets have shown 
that AVP is unable to block increases in cyclic 
AMP caused by activators of adenylate cyclase, 
although several other aggregating agents, such as 
ADP and epinephrine, readily do so [8]. More 
recently, AVP was also found to have no effect on 
cyclic AMP accumulation in cultured aortic 
smooth muscle cells [9]. In one apparently con- 
trary report [lo], AVP decreased cyclic AMP ac- 
cumulation in the presence L’ glucagon in rat 
hepatocytes, though the mechanism was not deter- 
mined. We have recently observed that platelet- 
activating factor can inhibit the adenylate cyclase 
activity of human platelet particulate fraction [ 111, 
although in intact platelets from this species no 
direct effect of this compound on cyclic AMP for- 
mation can be detected [12]. The latter apparently 
conflicting observations have prompted us to study 
340 
Published by Elsevier Scrence Publishers B. V. 
00145793/83/$3.00 8 1983 Federation of European Biochemical Societies 
Volume 164, number 2 FEBS LETTERS December 1983 
the effects of AVP and analogues on human 
platelet adenylate cyclase, using similar particulate 
fractions. We have found that AVP, like platelet- 
activating factor, possesses a latent ability to in- 
hibit human platelet adenylate cyclase. 
2. MATERIALS AND METHODS 
2.1. Materials 
Tris-ATP, disodium ATP (prepared by 
phosphorylation of adenosine and therefore essen- 
tially GTP-free), and Tris-phosphocreatine were 
obtained from Sigma (St. Louis, MO). dVDAVP 
was a generous gift from Dr M. Manning, Medical 
College of Ohio (Toledo, OH). [2,8-3H]ATP 
(29 Ci/mmol) was obtained from ICN (Irvine, 
CA). When the actions of GTP and NaCl were 
studied, the [3H]ATP was diluted with GTP-free 
disodium ATP to a specific activity of 
20 mCi/mmol and then eluted with water from a 
small column containing Dowex 50 resin (H+ 
form). The [3H]ATP obtained was adjusted to pH 
7.4 with Tris. All other materials were obtained 
from sources listed in [4] or [1 11. 
2.2. Preparation of platelet particulate fractions 
and assay of adenylate cyclase 
Human platelets were isolated and washed as in 
[4], except that they were finally resuspended at 
25 mg wet wt/ml in buffer (pH 7.4) containing 
150 mM Tris-HCl and 5 mM Tris-EGTA. After 
freezing and thawing this suspension, the par- 
ticulate fraction was isolated and resuspended for 
assay of adenylate cyclase as in [ 111, except that 
when the action of added GTP was studied, en- 
dogenous guanine nucleotides were removed by 
homogenization of the pellet in buffer containing 
10 mM Tris-HCl and 5 mM Tris-EGTA, pH 7.4. 
After centrifugation, this extraction procedure was 
repeated once more. In addition to the compounds 
specified in section 3, adenylate cyclase assay mix- 
turns (250~1) all contained 75 mM Tris-HCl (pH 
7.4), 5 mM MgC12, 0.4 mM Tris-[3H]ATP, 4 mM 
Tris-phosphocreatine, 20 units of creatine 
phosphokinase/ml, 1 mM cyclic AMP, 1 mM 
3-isobutyl-1-methylxanthine, 1 mg of crystallized 
bovine serum albumin/ml, 0.4 mM dithiothreitol 
and 0.4 mM Tris-EGTA. After incubation for 
10 min at 30°C assays were terminated and cyclic 
[3H]AMP isolated and quantitated [ll]. The 
platelet protein present in assays was measured as 
in [ll]. 
2.3. Measurement of changes in platelet cyclic 
~HJAMP 
Human heparinized platelet-rich plasma 
prepared as in [4] was labelled by incubation with 
2/M [3H]adenine for 90 min at 37°C. Samples 
(final vol. 0.5 ml containing 1.5-2.0 x 10’ 
platelets) were incubated at 37°C with appropriate 
additions. Incubations were terminated after 
0.5 min by addition of 1 ml of 15% (w/v) 
trichloroacetic acid. Cyclic [3H]AMP was isolated 
and quantitated as in [l I]. 
2.4. Measurement of platelet aggregation 
Aggregation of human platelets in heparinized 
platelet-rich plasma, prepared as in [4], was 
measured turbidimetrically using a Payton Ag- 
gregometer (Scarborough, Ont.). The change in 
light transmittance (A7) 0.5 min after addition of. 
AVP or analogues was determined. When an- 
tagonism of the action of AVP by dVDAVP was 
studied, platelets were incubated with dVDAVP 
for 20 s before addition of AVP. 
2.5. Analysis of dose-response curves 
To obtain best estimates of the concentrations of 
AVP causing half-maximal inhibition of adenylate 
cyclase (I& values) or half-maximal platelet ag- 
gregation (EC50 values), Hill plots of the results 
were constructed by linear regression. To avoid 
bias, only data points falling between 10 and 90% 
of the maximum effect were used. The inhibitory 
effects of dVDAVP on the actions of AVP were 
analyzed as in [ 131 to give pA2 values for 
dVDAVP. J&J or K’SO values, determined as 
above, were used to calculate the dose-ratio of 
AVP required to overcome the inhibitory effect of 
each concentration of dVDAVP studied. 
3. RESULTS 
When human platelet particulate fractions were 
washed to remove guanine nucleotides, addition of 
GTP alone had a biphasic effect on adenylate 
cyclase activity, tending to stimulate at low con- 
centrations (0.1 PM) and to inhibit at high concen- 
trations (10rM) (table 1). Enzyme activity was 
enhanced by 100 mM NaCl, particularly in the 
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Table 1 
Inhibition of the adenylate cyclase activity of human platelet particulate fraction by AVP; 
effects of NaCl and GTP 
Additions Adenylate cyclase activity Inhibition of 
(pm01 .mini . mg protein-‘) adenylate cyclase 
by AVP 
NaCl GTP Without AVP With AVP ((r/o) 
(mM) (uM) 
0 0 51.3 f 0.7 55.8 f 0.8 2+2 
0.1 66.6 f 0.7 58.3 f 1.0 12 + 2a 
10 41.8 f 0.8 35.5 k 0.8 15 f 3” 
100 0 69.1 f 1.3 64.8 k 0.3 6&2 
0.1 83.4 + 1.3 76.3 + 1.8 9+3 
10 14.3 + 0.9 55.1 f 0.9 26 + 2b 
= p < 0.05 
bp < 0.01 
The particulate fraction was washed twice with hypotonic buffer prior to resuspension for 
assay (see section 2). When present, AVP was 100 nM. Values for adenylate cyclase activity 
are means + SEM from 3 or 4 determinations. The significance of inhibition by AVP was 
determined using Student’s t-test 
presence of 10 pM GTP. Addition of AVP caused 
an inhibition of adenylate cyclase activity that was 
completely GTP-dependent and was potentiated 
by NaCl (table 1). Optimal inhibition was obtained 
in the presence of 10pM GTP, when 100 nM AVP 
decreased adenylate cyclase activity by 17 + 2% 
without NaCl (mean f SE, 6 expts) and by 27 + 
2% with 100 mM NaCl (mean + SE, 8 expts). 
Under these conditions, the AVP concentration re- 
quired for half-maximal inhibition was 1.2 f 
0.4 nM (7 expts). OVP caused the same maximal 
inhibition and was only slightly less potent (KSO = 
2.7 + 0.9 nM, 3 expts), but dVDAVP alone had no 
significant effect on platelet adenylate cyclase ac- 
tivity (fig.lA). However, dVDAVP was found to 
be a competitive inhibitor of the action of AVP on 
platelet adenylate cyclase (fig.2). Calculation gave 
a PAZ for dVDAVP of 7.74 + 0.04 (4 expts), which 
corresponds to a Ki of 18 + 2 nM. 
We were able to confirm our previous observa- 
tion that AVP has no effect on cyclic AMP forma- 
tion in intact platelets [8], using a wider range of 
AVP concentrations (10 nM-1 PM). These ex- 
periments were carried out with heparinized 
platelet-rich plasma containing platelets labelled 
by preincubation with t3H]adenine. Samples of 
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this material were incubated with indomethacin 
(10 PM), phosphocreatine (2 mM) and creatine 
phosphokinase (100 units/ml) for 5 min before ad- 
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Fig.1. Dose-response curves for: (A) the inhibition of 
platelet adenylate cyclase; (B) the induction of platelet 
aggregation by AVP (o), OVP (m) and dVDAVP (A). 
Values are means + SEM from 3 separate experiments. 
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Fig.2. Effects of different concentrations of dVDAVP 
on the dose-response curve for inhibition of adenylate 
cyclase by AVP. The dVDAVP concentrations used 
were: none (0); 100 nM (v); 400 nM (A); 2ooO nM (+). 
Values are means of 3 determinations. Inset: Schild plot 
of the effect of dVDAVP; dose-ratios (DR) of AVP 
causing half-maximal inhibition of adenylate cyclase at 
different dVDAVP concentrations were calculated as 
noted in section 2. 
dition of 0.2 PM prostaglandin E1 with or without 
AVP, to prevent any indirect inhibition of 
adenylate cyclase as a result of thromboxane AZ 
formation or the release of ADP. In these ex- 
9 
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Fig.3. Effects of different concentrations of dVDAVP 
on the dose-response curve for induction of platelet 
aggregation by AVP. The dVDAVP concentrations used 
were: none (0); 10 nM (+); 40 nM (v); 70 nM (A); 
200 nM (w). Inset: Schild plot of the effect of dVDAVP; 
dose-ratios (DR) of AVP causing half-maximal platelet 
aggregation at different dVDAVP concentrations were 
calculated as noted in section 2. 
periments, prostaglandin EI caused a lo-fold in- 
crease in platelet cyclic [3H]AMP but no inhibitory 
effect on this of any of the AVP concentrations 
tested was detected. 
Aggregation of platelets in heparinized platelet- 
rich plasma required much higher concentrations 
of AVP (EC50 = 27 f 4 nM, 4 expts) and OVP 
(EC50 = 41 + 8 nM, 3 expts) than were needed for 
inhibition of adenylate cyclase, but the relative ac- 
tivities of these two compounds were unaltered 
(fig. 1B). Addition of dVDAVP alone had no effect 
on human platelets (fig. 1B) but this compound was 
a potent competitive inhibitor of the aggregating 
action of AVP with a pA2 of 7.82 + 0.17 (6 expts) 
(fig.3). This p& value for dVDAVP corresponds 
to a Ki of 16 f 2 nM and does not differ 
significantly from that obtained when the com- 
pound was used to antagonize the inhibition of 
platelet adenylate cyclase by AVP. 
4. DISCUSSION 
The inhibition of platelet particulate fraction 
adenylate cyclase by AVP resembled the effects of 
other hormonal inhibitors of this enzyme in its 
dependence on a relatively high GTP concentra- 
tion [6,14]. Potentiation of the inhibitory effects 
of hormones on adenylate cyclase by NaCl is also 
a well-documented effect in many biological 
systems [6], though in the platelet this has only 
been observed when precautions have been taken 
to prevent endogenous Ca*+-dependent proteolysis 
[15]. Inhibition of adenylate cyclase with these 
characteristics i  considered to be a receptor effect 
mediated by the Ni GTP-binding protein [6,14]. 
This is the first description of such an effect of 
AVP. 
Our results indicate that the inhibition of 
adenylate cyclase by AVP is mediated by 
Vi-receptors. Thus, OVP has an enhanced ratio of 
vasopressor to antidiuretic activity (i.e., shows 
selectivity for Vi receptors), whereas dVDAVP is 
a potent antidiuretic (VZ) agonist and vasopressor 
(VI) antagonist [l]. The induction of platelet ag- 
gregation by AVP showed the same structural 
specificity as observed for the inhibition of 
adenylate cyclase. The identical PAZ values for in- 
hibition of both actions of AVP by dVDAVP are 
particularly significant and imply that very similar 
or identical receptors mediate both effects. Our 
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results show that a report claiming that platelet 
AVP receptors are of the renal VZ type [16] is in- 
correct and support the conclusion previously 
drawn by ourselves [4] and another group [5] 
regarding the specificity of these receptors. 
Although it is clear that platelet AVP receptors 
are of the VI type, our results do not exclude the 
possibility that different receptor subtypes are 
linked to the phosphoinositide breakdown 
associated with platelet aggregation induced by 
AVP [ 171 and to the inhibition of adenylate cyclase 
by this compound. More extensive analysis of the 
structure-activity relationships of a range of an- 
tagonists could reveal such a difference. However, 
it is also possible that different populations of 
identical AVP receptors are associated with the 
two different effector systems or that a single 
population links with one or the other system 
depending on the experimental conditions. The 
fact that no inhibition of adenylate cyclase by AVP 
could be detected in intact platelets favours the lat- 
ter hypothesis, and also suggests that unidentified 
factors may exist that regulate the effector system 
with which the AVP receptors interact. Such a 
possibility has been envisioned previously [6]. The 
same phenomenon, that is a latent capacity to in- 
hibit adenylate cyclase seen only in broken cell 
preparations, was also observed with respect o the 
effects of platelet-activating factor on human but 
not rabbit platelets [ 11,121. 
ACKNOWLEDGEMENT 
This work was supported by a grant (MT 5626) 
from the Medical Research Council of Canada. 
REFERENCES 
VI 
PI 
131 
141 
PI 
161 
171 
181 
191 
1101 
1111 
WI 
1131 
1141 
WI 
1161 
1171 
Sawyer, W.H., Grzonka, Z. and Manning, M. 
(1981) Mol. Cell. Endocrinol. 22, 117-134. 
Jard, S. (1983) Curr. Top. Membr. Tramp. 18, 
255-285. 
Michell, R.H., Kirk, C. J. and Billah, M.M. (1979) 
Biochem. Sot. Trans. 7, 861-865. 
Haslam, R.J. and Rosson, G.M. (1972) Am. J. 
Physiol. 223, 958-967. 
Thomas, M.E., Clare, K.A. and Scrutton, M.C. 
(1982) Br. J. Pharmacol. 75, 123P. 
Cooper, D.M.F. (1982) FEBS Lett. 138, 157-163. 
Jard, S., Cantau, B. and Jakobs, K.H. (1981) J. 
Biol. Chem. 256, 2603-2606. 
Haslam, R.J. (1975) in: Biochemistry and 
Pharmacology of Platelets, Ciba Foundation 
Symposium 35, 121-151, Elsevier, Amsterdam, 
New York. 
Penit, J., Faure, M. and Jard, S. (1983) Am. J. 
Physiol. 244, E72-E82. 
Crane, J.K., Campanile, C.P. and Garrison, J.C. 
(1982) J. Biol. Chem. 257, 4959-4965. 
Haslam, R.J. and Vanderwel, M. (1982) J. Biol. 
Chem. 257, 6879-6885. 
Miller, O.V., Ayer, D.E. and Gorman, R.R. (1982) 
Biochim. Biophys. Acta 711, 445-451. 
Arunlakshana, 0. and Schild, H.O. (1959) Br. J. 
Pharmacol. 14, 48-58. 
Jakobs, K.H., Aktories, K. and Schultz, G. (1983) 
J. Receptor Res. 3, 137-149. 
Williams, K. and Haslam, R.J. (1983) Fed. Proc. 
42, 1027. 
Berrettini, W.H., Post, R.M., Worthington, E.K. 
and Caspar, J.B. (1982) Life Sci. 30, 425-432. 
Brydon, L.J., Pollock, W.K., Shaw, A.M., 
Drummond, A.H. and MacIntyre, D.E. (1983) 
Thrombos. Haemostas. 50, 47. 
344 
